Physician profile
Christopher Burrell
NPI 1992361778
$1,308.72
in general payments reported to CMS, 2019-2025
9 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.71 · 2024: $355 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.71 | 2023-2025 | Ubrelvy |
| Neurocrine Biosciences, INC. | $55.38 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $48.54 | 2024-2025 | Vyepti |
| Apellis Pharmaceuticals, INC. | $46.81 | 2024 | Syfovre |
| Neurelis, INC. | $21.76 | 2025 | Valtoco |
| Xeris Pharmaceuticals, INC. | $20.77 | 2025 | Keveyis |
| Acadia Pharmaceuticals INC | $20.19 | 2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $19.05 | 2025 | Xeomin, Ampyra, Inbrija |
| Biotissue Holdings INC. | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.